I just bought a small amount of Adept Technology (ADEP) at $5.92 a share. I'll be watching to see if future developments warrant further investment.
Adept Technology is a small cap company that makes industrial robots. It has been around for quite a while. I like robots. This is my second go round with Adept. Despite my trying to be a long-term investor, and my shifting to biotechnology stocks, I bailed out of ADEP once already, and with good reason. If you do decide you like ADEP, be wary.
I originally bought Adept in 2012, when it was in deep trouble due to falling sales. I bought at $3.95 on 11/5/2012 and then at $2.94 on 11/09/2012. My final purchase was for $3.34 on 2/8/2013.
It was a turn around bet, and after Adept hit bottom some small brokerages started recommending it. The stock rose faster than its revenue, and so I started selling. I sold at $7.92 on 10/7/2013, then at $14.45 on 12/26/2013, and the remainder at $18.63 on 2/10/ 2014. The stock went even higher than that, but neither sales nor profits justified the high prices, to me.
Of course eventually the stock price stalled and started falling. I continued to cover Adept at OpenIcon. You can read my notes about the Adept Technology March 2015 quarter results and analyst conference.
My reasoning for today's purchase is that the current market cap is about $80 million. In March revenue was $14.1 million, and June quarter guidance is for revenue between $13.5 and $15.0 million. Margins are not great, so they are losing money, but could hit profitability on a bit more revenue.
But feedback on their mobile robots (for warehouses, etc.) is good, and they expect to sell significantly more as the year progresses, though perhaps in a lumpy manner.
My rule of thumb for P/E is 20. So they need $4 million per year, or $1 million per quarter, to justify the current price. I think Adept could reach $1 million profit per quarter by the end of the year. They could also fail for a variety of reasons, including less than expected sales of their old-line, assembly-line robots, or of the new mobile robots.
Again, I hope that Adept succeeds gradually, and the stock price just goes up to reflect the level of success. So I can be a happy, long term investor, rather than having to sell after concluding that the stock price has been pumped up beyond reason.
Especially when investing in micro-cap stocks it really pays to
Keep Diversified!
Showing posts with label Adept Technology. Show all posts
Showing posts with label Adept Technology. Show all posts
Tuesday, May 5, 2015
Thursday, February 5, 2015
Dot Hill, Adept Technology
I own and like data storage equipment maker Dot Hill (HILL), but wrote an article for Seeking Alpha in which I tried to be objective about both the opportunity and the reasons it might not work out:
Dot Hill's Q1 Guidance Will be Critical
As to Adept Technology, I want to emphasize that I don't dislike their technology or management. What I disliked was the run up of the stock price far past any reasonable valuation. To justify the valuation before yesterday's earnings report would have required a substantial climb in revenue, but instead there was a substantial decline in Q4. So the stock price plunged today. I did not even listen to the analyst call once I saw the press release. So if you want Q4 results you might as well go to the Adept Technology Q4 2014 press release.
Dot Hill's Q1 Guidance Will be Critical
As to Adept Technology, I want to emphasize that I don't dislike their technology or management. What I disliked was the run up of the stock price far past any reasonable valuation. To justify the valuation before yesterday's earnings report would have required a substantial climb in revenue, but instead there was a substantial decline in Q4. So the stock price plunged today. I did not even listen to the analyst call once I saw the press release. So if you want Q4 results you might as well go to the Adept Technology Q4 2014 press release.
Wednesday, August 27, 2014
Mylan, Adept Technology updates
I have a new article at Seeking Alpha on generic drug manufacturer Mylan (MYL):
Mylan: Deeply Undervalued On Unwarranted Approval Concerns
I began following Mylan in earnest in Q2 of 2013. I first bought some Mylan on March 20, 2014. I expect Mylan to double by the end of 2015 (expect in the sense of the center of the probability curve. Results can vary).
This is a (thankfully) slow week, but on Monday Adept Technology (ADEP) reported disappointing results. My summary is Adept Technology Q2 2014 analyst conference notes. I would like to see this robotics company grow and reward investors, but I think it is overpriced at the moment. I first bought in November of 2012 for $3.95 when it was in an even worse situation than it is now. I bought it for as low as $2.94, but when it started to grow sales again some brokerages started hyping it and I sold for as high as $17.10, which was not even as high as it went before it plunged back down to reality, which today was $8.75 per share.
At $8.75 per share market cap is $114.6 million. But annualized revenue is only in the vicinity of $60 million, and ADEP remains in the red, though close to break even. If revenues double and profits ramp the $8.75 would be justified. Adept has a good, diverse robot product line, including robots for warehouse work, so it could happen. I'll continue to report on it, but to buy back in I would need to see a lower stock price or a quarter with over $18 million in revenue with some sort of guidance to a sequentially higher quarter.
Mylan: Deeply Undervalued On Unwarranted Approval Concerns
I began following Mylan in earnest in Q2 of 2013. I first bought some Mylan on March 20, 2014. I expect Mylan to double by the end of 2015 (expect in the sense of the center of the probability curve. Results can vary).
This is a (thankfully) slow week, but on Monday Adept Technology (ADEP) reported disappointing results. My summary is Adept Technology Q2 2014 analyst conference notes. I would like to see this robotics company grow and reward investors, but I think it is overpriced at the moment. I first bought in November of 2012 for $3.95 when it was in an even worse situation than it is now. I bought it for as low as $2.94, but when it started to grow sales again some brokerages started hyping it and I sold for as high as $17.10, which was not even as high as it went before it plunged back down to reality, which today was $8.75 per share.
At $8.75 per share market cap is $114.6 million. But annualized revenue is only in the vicinity of $60 million, and ADEP remains in the red, though close to break even. If revenues double and profits ramp the $8.75 would be justified. Adept has a good, diverse robot product line, including robots for warehouse work, so it could happen. I'll continue to report on it, but to buy back in I would need to see a lower stock price or a quarter with over $18 million in revenue with some sort of guidance to a sequentially higher quarter.
Tuesday, February 11, 2014
Adept Technology, TTM Technologies, and Regeneron Analyst Call Notes
I have posted my notes on the following quarter results and analyst conference calls:
Adept Technology (ADEP) Q4 2013 analyst call notes
TTM Technologies (TTMI) Q4 2013 analyst call notes
Regeneron (REGN) Q4 2013 analyst call notes
I own shares of TTMI. I do not own shares of REGN but may buy shares at any time.
I disposed of my remaining shares of ADEP yesterday. This is not a reflection of the company or its management. They have turned the company around and are set up to sell significantly more industrial robots as time passes. It is purely a valuation call: too high, too fast for me. I may buy ADEP shares again at any price point should I feel that is warranted.
Adept Technology (ADEP) Q4 2013 analyst call notes
TTM Technologies (TTMI) Q4 2013 analyst call notes
Regeneron (REGN) Q4 2013 analyst call notes
I own shares of TTMI. I do not own shares of REGN but may buy shares at any time.
I disposed of my remaining shares of ADEP yesterday. This is not a reflection of the company or its management. They have turned the company around and are set up to sell significantly more industrial robots as time passes. It is purely a valuation call: too high, too fast for me. I may buy ADEP shares again at any price point should I feel that is warranted.
Tuesday, December 31, 2013
My Great 2013 stock investments
My portfolio did so well -- so much better than the stock indexes -- in 2013 that I have to keep telling myself, my wife, and anyone else who cares to know that this is not repeatable. This qws a once in a lifetime year.
I am a long term investor, and for the most part just held the stocks I began the year with. I did trade, trimming in and out, a bit more than usual. One stock, Onyx Pharmaceuticals, was acquired by Amgen. I added positions in just two stocks, Agenus (AGEN) and (PLX). I dropped my position in FNHC, mainly because it had a big runnup and I cover it, so I was worried about maintaining objectivity.
On the whole I was up 79%. Just plain stocks. No options, leveraging, or shorting.
So here's the list of companies I owned both at the beginning of 2013 and at the end:
I am a long term investor, and for the most part just held the stocks I began the year with. I did trade, trimming in and out, a bit more than usual. One stock, Onyx Pharmaceuticals, was acquired by Amgen. I added positions in just two stocks, Agenus (AGEN) and (PLX). I dropped my position in FNHC, mainly because it had a big runnup and I cover it, so I was worried about maintaining objectivity.
On the whole I was up 79%. Just plain stocks. No options, leveraging, or shorting.
So here's the list of companies I owned both at the beginning of 2013 and at the end:
| Symbol | end price 2012 | end price 2013 | % change |
| ADEP | $2.38 | $16.89 | 610% |
| AMAT | 11.20 | 17.68 | 58% |
| AMD | 2.40 | 3.87 | 61% |
| BIIB | 146.37 | 279.57 | 91% |
| CELG | 78.47 | 168.97 | 115% |
| CMN | 19.82 | 33.91 | 72% |
| CYCC | 6.06 | 4.02 | -34% |
| DNDN | 5.29 | 2.99 | -43% |
| GILD | 36.72 | 75.10 | 104% |
| HILL | 0.85 | 3.37 | 296% |
| HNSN | 2.08 | 1.73 | -17% |
| INO | 0.46 | 2.90 | 530% |
| MCHP | 31.80 | 44.75 | 41% |
| MRVL | 7.08 | 14.38 | 103% |
| SGI | 10.23 | 13.41 | 31% |
| STX | 29.80 | 56.16 | 88% |
| TTMI | 9.19 | 8.58 | -7% |
I've written extensively about most of these stocks, so here I'll just make brief year-closing comments on the 3 best percentage gainers, and the 3 worst. Worst first.
Proving I am not prescient we have Dendreon (DNDN). I once made a lot of money on Dendreon, but 2013 was a rough year. Its single approved therapy, Provenge, is not doing well against competition. In addition, Provenge is very expensive to make. Even approval for sale in Europe did little for the stock.
Cyclacel (CYCC), which is in a pivotal Phase III trial for leukemia (AML) in elderly people too old to do chemotherapy, lost 34%. That is surprising because the data during 2013 was pretty good: the independent data monitoring agency allowed the trial to continue after the half-way point, indicating the data so far shows the drug to be safe and effective. It is still a gamble, but it is a company to watch in 2015.
Hansen Medical (HNSN), a maker of surgical robotic catheters, had a mediocre year as sales did not ramp as well as expected. Maybe the Q4 report will be better. The technology is promising, but I'd be surprised if they get in the black in 2014.
As to the winners, from 3rd to 1st place:
Dot Hill (HILL), up 296% this year, is a little-train-that-could story. The data storage equipment maker landed a number of new clients in 2013, got back into the black after years in the red, and looks to be headed to a good 2014.
Inovio (INO) was up 530% when people finally realized that its DNA vaccine technology could be a major breakthrough. However, they don't even have successful data from a Phase II trial yet. What works in the test tube and in animals and Phase I trials may not ever make it to commercialization. I like the company, but I'd like it better with more concrete data.
Who, at the beginning of the year, would have thought Adept Technology (ADEP) would have a 610% year? The stock started cheap because they had a bad 2011-2012, with customers cutting back on orders of their industrial robots. So they cut expenses and in 2013 introduced new lines of robots and landed new customers. The price has also been driven up by momentum traders. Check it out, but you might want to see Q4 results before you take a plunge.
I am a professional researcher, analyst, and writer. I write about my personal experience with investing for fun. You can follow me at this blog site, at www.openicon.com, or at William Meyers at Seeking Alpha.
Labels:
2013,
Adept Technology,
Cyclacel,
Dendreon,
Dot Hill,
Hansen Medical,
Inovio,
stock market
Wednesday, August 28, 2013
Alexion Pharmaceuticals and Adept Technology
I have added Alexion Pharmaceuticals (ALXN), a creator of therapies for blood disorders, to my list of covered stocks. I do not currently own ALXN. You can read my Seeking Alpha article: Alexion Pharmaceuticals Offers Long-Term Value or look at my notes from the latest analyst call, Alexion Pharmaceuticals Q2 2013 Analyst Conference Summary.
Connected only by alliteration, we have robot manufacturer Adept Technology (ADEP), which had quite a stock boost today based on June quarter (fiscal Q4) results. My notes are at Adept Technology Q4 2013 Analyst Call Summary. You can see my prior prediction that this should be a turn-around quarter at Adept Technology Order May Signal Turnaround published at Seeking Alpha on June 28, 2013.
I do own ADEP stock.
Connected only by alliteration, we have robot manufacturer Adept Technology (ADEP), which had quite a stock boost today based on June quarter (fiscal Q4) results. My notes are at Adept Technology Q4 2013 Analyst Call Summary. You can see my prior prediction that this should be a turn-around quarter at Adept Technology Order May Signal Turnaround published at Seeking Alpha on June 28, 2013.
I do own ADEP stock.
Labels:
ADEP,
Adept Technology,
Alexion Pharmaceuticals,
ALXN,
robots
Monday, November 5, 2012
I Buy Adept Technology (ADEP)
Just a brief note that I bought a small initial position in Adept Technologies, symbol ADEP. You can read my prior assessment at Adept Technology First Look.
This is a very long term investment for me. I have no reason to think Adept is going to go up in price in the near future. There will be an Adept Technology conference call on November 8, this Thursday. I will take notes on it and post them. See my Adept Technology Analyst Conferences page for a link.
I decided to go ahead with the ADEP purchase because I believe there is a future in robotics and that Adept is addressing a significant unmet need. Adept has grown both by acquisitions and by organic growth and appears to be well-managed. Needless to say, that does not guarantee success.
So keep diversified!
This is a very long term investment for me. I have no reason to think Adept is going to go up in price in the near future. There will be an Adept Technology conference call on November 8, this Thursday. I will take notes on it and post them. See my Adept Technology Analyst Conferences page for a link.
I decided to go ahead with the ADEP purchase because I believe there is a future in robotics and that Adept is addressing a significant unmet need. Adept has grown both by acquisitions and by organic growth and appears to be well-managed. Needless to say, that does not guarantee success.
So keep diversified!
Thursday, August 30, 2012
Adept Technology (ADEP) Initial Look
Adept Technology is a Pleasanton, California based maker of robotic machines for materials handling. I was mentioned in a New York Times article recently, which I read because of my interest in robots and artificial intelligence. I decided to take a look at the company as a potential investment. Yesterday Adept (ADEP) released its June quarter (fiscal Q4) results, and I listened to the analyst conference. You can read my notes at: Adept Technology fiscal Q4 2012 notes.
The first thing that individual investors should note is the Adept has a small market capitalization and is not yet profitable. Revenue in the quarter was substantial, however, at $17 million. Net income was negative $360,000, which is within sight of break-even. However bright the future of robotics and Adept might be, it needs to be treated as a risky stock. The stock price ran up after the Times article, and is falling today along with most of the market. Right now it is at $4.30, which would give it a market capitalization of $45.3 million.
I certainly don't consider a young technology company with an annual revenue run rate approaching $70 million to be overpriced when the market cap is $45.3 million and it is running near break-even.
Judging mainly from the conference, Adept makes three basic types of robots, all of which are based on artificial intelligence applied to video, as well as the usual need to manipulate the robots themselves. It mainstay is robots used in the manufacture of hard disk drives.
It has also introduced robots for handling semiconductor wafers, and has a first client for these mobile robots in Singapore.
A third line is designed to rapidly pack agricultural products in plastic clamshell packaging, and there is a California company that is the first customer and proving ground for this product.
It is tempting to plunge in and buy an initial stake of ADEP, but I am going to follow my usual path of being patient and doing more research. There are many robotics companies already, and while there are a lot of applications that could benefit from robots, it is important to understand the competition. Also, I need to read the more recent SEC filings, which I have not done yet.
I already own stock in a medical robotics company, Hansen Medical, and in a manufacturer of microcontrollers used in robotics, Microchip.
I should mention that Adept raised $3 million in the quarter through a new stock issue, and has less than $9 million in cash on hand. In addition to stock dilution through stock-based compensation, there could be a need to raise more cash.
Going forward, I would hope to see better margins on the newer robot lines. If they are valuable to customers, they should be valuable enough to price at a point where there are profit margins for Adept. Otherwise they are just having fun with robots and are not an investment-grade company.
My initial impression of Adept Technologies is very positive overall. At the same time there are a lot of alternatives for my (or your) investment cash. If I do start buying Adept I probably will report that only after the fact. Often I follow stocks for years without ever buying in.
Disclaimer: I have no relationship to ADEP and currently do not own stock. I may buy ADEP at any point without prior notice
See also: http://www.adept.com/
The first thing that individual investors should note is the Adept has a small market capitalization and is not yet profitable. Revenue in the quarter was substantial, however, at $17 million. Net income was negative $360,000, which is within sight of break-even. However bright the future of robotics and Adept might be, it needs to be treated as a risky stock. The stock price ran up after the Times article, and is falling today along with most of the market. Right now it is at $4.30, which would give it a market capitalization of $45.3 million.
I certainly don't consider a young technology company with an annual revenue run rate approaching $70 million to be overpriced when the market cap is $45.3 million and it is running near break-even.
Judging mainly from the conference, Adept makes three basic types of robots, all of which are based on artificial intelligence applied to video, as well as the usual need to manipulate the robots themselves. It mainstay is robots used in the manufacture of hard disk drives.
It has also introduced robots for handling semiconductor wafers, and has a first client for these mobile robots in Singapore.
A third line is designed to rapidly pack agricultural products in plastic clamshell packaging, and there is a California company that is the first customer and proving ground for this product.
It is tempting to plunge in and buy an initial stake of ADEP, but I am going to follow my usual path of being patient and doing more research. There are many robotics companies already, and while there are a lot of applications that could benefit from robots, it is important to understand the competition. Also, I need to read the more recent SEC filings, which I have not done yet.
I already own stock in a medical robotics company, Hansen Medical, and in a manufacturer of microcontrollers used in robotics, Microchip.
I should mention that Adept raised $3 million in the quarter through a new stock issue, and has less than $9 million in cash on hand. In addition to stock dilution through stock-based compensation, there could be a need to raise more cash.
Going forward, I would hope to see better margins on the newer robot lines. If they are valuable to customers, they should be valuable enough to price at a point where there are profit margins for Adept. Otherwise they are just having fun with robots and are not an investment-grade company.
My initial impression of Adept Technologies is very positive overall. At the same time there are a lot of alternatives for my (or your) investment cash. If I do start buying Adept I probably will report that only after the fact. Often I follow stocks for years without ever buying in.
Disclaimer: I have no relationship to ADEP and currently do not own stock. I may buy ADEP at any point without prior notice
See also: http://www.adept.com/
Subscribe to:
Posts (Atom)
